- Home
- RPRX
RPRX
Royalty Pharma plc
as 07-26-2024 4:00pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 12.8B | IPO Year: | 2020 |
| Target Price: | $41.80 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.77 | EPS Growth: | 139.19 |
| 52 Week Low/High: | $25.20 - $31.66 | Next Earning Date: | 08-08-2024 |
| Revenue: | $2,238,561,000 | Revenue Growth: | -5.11% |
| Revenue Growth (this year): | 12.68% | Revenue Growth (next year): | 10.40% |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $28.52 | 235,200 | $6,707,080.80 | 254,899 | SEC Form 4 |
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $27.79 | 199,098 | $5,532,276.40 | 55,801 | SEC Form 4 |
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $27.55 | 35,702 | $983,504.42 | 20,099 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 29 '23 | Sell | $28.04 | 65,803 | $1,845,405.65 | 2,477,520 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 27 '23 | Sell | $28.01 | 41,729 | $1,168,754.18 | 2,753,186 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 27 '23 | Sell | $28.20 | 209,863 | $5,918,934.08 | 2,543,323 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 15 '23 | Sell | $28.01 | 10,229 | $286,498.95 | 2,794,915 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 13 '23 | Sell | $28.95 | 307,935 | $8,916,011.58 | 3,169,585 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 13 '23 | Sell | $28.91 | 364,441 | $10,534,276.44 | 2,805,144 | SEC Form 4 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
Simply Wall St.
5 days ago
Royalty Pharma (NASDAQ:RPRX) Is Due To Pay A Dividend Of $0.21
GlobeNewswire
7 days ago
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
9 days ago
Royalty Pharma Declares Third Quarter 2024 Dividend
Insider Monkey
24 days ago
Is Royalty Pharma plc (RPRX) a Good Stock to Buy Now?
Simply Wall St.
a month ago
Royalty Pharma plc (NASDAQ:RPRX) is largely controlled by institutional shareholders who own 70% of the company
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.